Although tumor-targeting peptides like our PD-L1-, EGFR-, and ER-targeting motifs are typically less immunogenic than protein biologics [5,18], antibody or T-cell responses can still occur, especially with repeated dosing or modified sequences. This evidence concerns the gene EGFR and neoplasm.